almotriptan has been researched along with cilostazol in 1 studies
| Studies (almotriptan) | Trials (almotriptan) | Recent Studies (post-2010) (almotriptan) | Studies (cilostazol) | Trials (cilostazol) | Recent Studies (post-2010) (cilostazol) |
|---|---|---|---|---|---|
| 188 | 59 | 42 | 1,508 | 302 | 848 |
| Protein | Taxonomy | almotriptan (IC50) | cilostazol (IC50) |
|---|---|---|---|
| Cytochrome P450 2C9 | Homo sapiens (human) | 10 | |
| cGMP-inhibited 3',5'-cyclic phosphodiesterase B | Homo sapiens (human) | 0.4367 | |
| cGMP-inhibited 3',5'-cyclic phosphodiesterase A | Homo sapiens (human) | 0.3285 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
1 review(s) available for almotriptan and cilostazol
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |